LAWRENCEVILLE, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage

Gainers Elutia (NASDAQ:ELUT) stock moved upwards by 17.2% to $0.94 during Thursday's after-mark

Unique investment vehicle provides efficient access to equity capitalOutstanding debt of the origina

2026 R&D Day presentation highlights include:Review of final Randomized Phase 2 overall survival

2026 R&D Day presentation highlights include: Review of final Randomized Phase 2 overall survival re

Imunon, Inc. (IMNN) Shareholder/Analyst Call Transcript

Independent Data Monitoring Committee recommends the ongoing Phase 2 MRD study continue without modi

Independent Data Monitoring Committee recommends the ongoing Phase 2 MRD study continue without modi

Collaboration with NCI's Cancer Therapy Evaluation Program (CTEP) will evaluate IMNN-001in new i

Collaboration with NCI's Cancer Therapy Evaluation Program (CTEP) will evaluate IMNN-001in new indic

Gainers Tenon Medical (NASDAQ:TNON) stock moved upwards by 48.8% to $3.63 during Thursday's pre

IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunoth

Investors, media and stakeholders are invited to join in person in New York City or via live webcast

Leading oncology experts and company management will discuss the Phase 3 OVATION 3 study, supporting

Imunon, Inc. (IMNN) Q2 2026 Earnings Call Transcript

Imunon (NASDAQ:IMNN) reported quarterly losses of $(0.54) per share which beat the analyst consensus

Gainers AbCellera Biologics (NASDAQ:ABCL) shares increased by 8.2% to $7.5 during Friday's afte

Enrollment momentum exceeding expectations is based on highly promising survival (OS) data and well

IMUNON posts rapid patient enrollment in its Phase 3 OVATION 3 trial for ovarian cancer, targeting c

Translational and clinical data reinforce IMNN-001's potential to unlock IL-12's anti-tumor

Translational and clinical data reinforce IMNN-001's potential to unlock IL-12's anti-tumor power in

Preliminary data reinforces IMNN-001 immunotherapy's potential for success in the rapidly recruiting

Imunon Inc. (NASDAQ:IMNN) on Tuesday reported new preliminary findings from its ongoing Phase 2 mini

Imunon reports early Phase 2 data showing lower residual disease and higher ctDNA clearance with IMN

Gainers Jupiter Neurosciences (NASDAQ:JUNS) stock rose 36.4% to $0.23 during Tuesday's pre-mark

 On June 29, 2026, Jeffrey Church informed Imunon, Inc. (the "Company") of his intent to ret

IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated im

On track for enrollment of 80 participants by Q1 2027 Trial is supported by Phase 2 results showing

LAWRENCEVILLE, N. J. , June 22, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-sta

Includes up-front issuance of preferred stock for $2.5 million and secured promissory notes for $7.7

Includes up-front issuance of preferred stock for $2.5 million and secured promissory notes for $7.7

Imunon, Inc. (IMNN) Q1 2026 Earnings Call Transcript

Imunon (NASDAQ:IMNN) reported quarterly losses of $(0.84) per share which beat the analyst consensus

IMNN-001 is the First and Only frontline treatment candidate to demonstrate the potential for a clin

Maxim Group analyst Jason McCarthy initiates coverage on Imunon (NASDAQ:IMNN) with a Buy rating a